BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32826945)

  • 1. Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.
    Park JW; Kang JY; Hahm JY; Kim HJ; Seo SB
    Commun Biol; 2020 Aug; 3(1):462. PubMed ID: 32826945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
    Wang X; Lu G; Li L; Yi J; Yan K; Wang Y; Zhu B; Kuang J; Lin M; Zhang S; Shao G
    Biochem Biophys Res Commun; 2014 Feb; 444(3):290-5. PubMed ID: 24342616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.
    Wang X; Lu G; Li L; Yi J; Yan K; Wang Y; Zhu B; Kuang J; Lin M; Zhang S; Shao G
    Biochem Biophys Res Commun; 2014 Feb; 444(4):549-54. PubMed ID: 24472556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
    Tan Y; Ci Y; Dai X; Wu F; Guo J; Liu D; North BJ; Huo J; Zhang J
    Oncotarget; 2017 Jul; 8(29):47890-47901. PubMed ID: 28599312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
    Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
    Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
    Zhu L; Yu CL; Zheng Y
    Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of NSD2 Suppresses Renal Cell Carcinoma Metastasis by Inhibiting Epithelial-Mesenchymal Transition.
    Han X; Piao L; Yuan X; Wang L; Liu Z; He X
    Int J Med Sci; 2019; 16(10):1404-1411. PubMed ID: 31692936
    [No Abstract]   [Full Text] [Related]  

  • 13. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
    Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
    Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone methyltransferase, NSD2, enhances androgen receptor-mediated transcription.
    Kang HB; Choi Y; Lee JM; Choi KC; Kim HC; Yoo JY; Lee YH; Yoon HG
    FEBS Lett; 2009 Jun; 583(12):1880-6. PubMed ID: 19481544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ligase SCF
    Thacker G; Mishra M; Sharma A; Singh AK; Sanyal S; Trivedi AK
    Life Sci; 2020 Sep; 257():118041. PubMed ID: 32622945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
    Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
    J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
    Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
    Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
    Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
    J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.